Calvin Goforth, PhD

Calvin Goforth, PhD
Calvin Goforth, PhD, VIC Founder and Chief Executive Officer, has extensive experience in start-up company development in founder, investor, board member, and executive roles. His experience encompasses intellectual property assessment, building strong development teams, raising private investment and government funding, and bringing products to market. He received a BS in Aerospace Engineering with Highest Honors from the University of Texas at Austin.
Find me on:

Recent Posts

University Technology Licensing Part 2: Assessing the Opportunities and Negotiating Licenses

Part 2: Technology Transfer and License Terms As was described in Part I of this article [1], VIC has a systematic and thorough technology assessment process. We also have extensive experience negotiating licenses for...

University Technology Licensing: Assessing the Opportunities and Negotiating Licenses

Part 1: Opportunity Sourcing and Assessment The U.S. invests more than $120 billion in federally sponsored research funding at universities and national labs. Technology Transfer Offices (TTOs) are unique entities...

Building Life Science Startups Beyond Traditional Venture Capital Hubs

Innovation is Geographically Distributed; Venture Capital Activity is Not The powerful combination of venture capital and innovation is critical to maintaining the global competitiveness of the U.S. While innovation is...

Zero Federal Capital Gains Taxes on High-Return Investments

With a new administration comes new perspectives and likely changes in tax policy. President Biden has proposed doubling the rate that wealthy Americans pay on investment capital gains up to 43.4%, a topic that has been...

Protecting Early Investors in Capital-Intensive Life Science Companies

Angel investors often invest at the seed stage of a company's development. The typically smaller round sizes and lower valuations allow early individual investors to gain a meaningful stake in a given company. However,...

A Letter from our CEO

When I wrote my last “letter from the CEO” in January 2020, I did not foresee the tumultuous year ahead. For so many, it’s been a tragic and difficult year on a personal level. We have all been impacted by the pandemic...

VIC Investor Network Introduces a Secondary Market for Members

Provides VIN Members Early Liquidity Options FAYETTEVILLE, AR. DECEMBER 14, 2020- The VIC Investor Network (“VIN”) makes investments into companies based on technologies that can have substantial impact on human health...

VIC Foundry: An Incubator for High Impact Life Science Technologies

What is VIC Foundry? VIC Foundry is one element of the VIC innovation ecosystem. It develops technologies sourced from top research institutions in the U.S. with the potential to have substantial impact and commercial...

VIC 2020 Mid-Year Update

So far, in 2020, VIC’s portfolio of companies reached numerous milestones and potential business partners are increasingly finding ways to re-engage in spite of the ongoing pandemic. The VIC Foundry has expanded...

Why VIC Sometimes Steps Outside Its Life Science Focus

VIC Technology Venture Development primarily is focused on building companies around high-impact life science technologies, including medical devices, therapeutics, diagnostics, and advanced instrumentation. More than...

FEATURED RESOURCES

Insight
Zero Federal Capital Gains Taxes on High-Return Investments
White Paper
Portfolio Diversification in Times of Market Volatility
Insight
Protecting Early Investors in Capital-Intensive Life Science Companies
Interview
Inside Blackstone LaunchPad at UT Southwestern Medical Center with Brad Phelan
White Paper
University Technology Licensing: Assessing the Opportunities and Negotiating Licenses
Updates
VIC 2021 Mid-Year Update Executive Summary
News
Solaris Vaccines Formed to Develop and Commercialize a Rapid, Flexible Vaccine Manufacturing Platform
Interview
VIC Fellows Spotlight: Evan Goldberg, PhD
From The Corner Office
SFC Fluidics Nears FDA Submission